We identified 1,749 junctions that were significantly differentially used between the SF3B1 mutant and SF3B1 wild-type samples across the three tumor types including 1,330 novel junctions, of which 1,117 are novel 3’SSs (BH-adjusted p < 0.1, S2 File). Here, SF3B1 is linked to neoplasm.